Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: AstraZeneca
A PHASE1/PHASE2 clinical study on Head and Neck Neoplasms, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 13 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Mar 2023 — Jun 2023 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 8 earlier versions
-
Mar 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Innate Pharma
For direct contact, visit the study record on ClinicalTrials.gov .